CN112043829A - 使用hedgehog途径抑制剂对增殖性病症的治疗和预后监测 - Google Patents

使用hedgehog途径抑制剂对增殖性病症的治疗和预后监测 Download PDF

Info

Publication number
CN112043829A
CN112043829A CN202010765711.3A CN202010765711A CN112043829A CN 112043829 A CN112043829 A CN 112043829A CN 202010765711 A CN202010765711 A CN 202010765711A CN 112043829 A CN112043829 A CN 112043829A
Authority
CN
China
Prior art keywords
hhp
psa
hhp inhibitor
cancer
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202010765711.3A
Other languages
English (en)
Chinese (zh)
Inventor
尼古拉斯·J·维尔坎
小弗朗西斯·E·奥唐奈
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mayne Pharma International Pty Ltd
Original Assignee
Mayne Pharma International Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mayne Pharma International Pty Ltd filed Critical Mayne Pharma International Pty Ltd
Publication of CN112043829A publication Critical patent/CN112043829A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96433—Serine endopeptidases (3.4.21)
    • G01N2333/96441—Serine endopeptidases (3.4.21) with definite EC number
    • G01N2333/96455—Kallikrein (3.4.21.34; 3.4.21.35)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
CN202010765711.3A 2013-04-17 2014-04-16 使用hedgehog途径抑制剂对增殖性病症的治疗和预后监测 Pending CN112043829A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201361813122P 2013-04-17 2013-04-17
US61/813,122 2013-04-17
US201361831823P 2013-06-06 2013-06-06
US61/831,823 2013-06-06
US14/173,588 2014-02-05
US14/173,588 US9192609B2 (en) 2013-04-17 2014-02-05 Treatment and prognostic monitoring of proliferation disorders using hedgehog pathway inhibitors
CN201480034571.5A CN105722512A (zh) 2013-04-17 2014-04-16 使用hedgehog途径抑制剂对增殖性病症的治疗和预后监测

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201480034571.5A Division CN105722512A (zh) 2013-04-17 2014-04-16 使用hedgehog途径抑制剂对增殖性病症的治疗和预后监测

Publications (1)

Publication Number Publication Date
CN112043829A true CN112043829A (zh) 2020-12-08

Family

ID=51729477

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202010765711.3A Pending CN112043829A (zh) 2013-04-17 2014-04-16 使用hedgehog途径抑制剂对增殖性病症的治疗和预后监测
CN201480034571.5A Pending CN105722512A (zh) 2013-04-17 2014-04-16 使用hedgehog途径抑制剂对增殖性病症的治疗和预后监测

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201480034571.5A Pending CN105722512A (zh) 2013-04-17 2014-04-16 使用hedgehog途径抑制剂对增殖性病症的治疗和预后监测

Country Status (14)

Country Link
US (10) US9192609B2 (enExample)
EP (1) EP2986296B1 (enExample)
JP (2) JP2016518371A (enExample)
KR (1) KR20160053843A (enExample)
CN (2) CN112043829A (enExample)
AU (2) AU2014253998A1 (enExample)
BR (1) BR112015025944A8 (enExample)
CA (1) CA2909290C (enExample)
DK (1) DK2986296T3 (enExample)
ES (1) ES3033763T3 (enExample)
HU (1) HUE071728T2 (enExample)
MX (1) MX383296B (enExample)
PL (1) PL2986296T3 (enExample)
WO (1) WO2014172456A1 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9264013B2 (en) * 2013-06-04 2016-02-16 Qualcomm Incorporated Systems for reducing magnetic coupling in integrated circuits (ICS), and related components and methods
WO2016037194A1 (en) * 2014-09-05 2016-03-10 The Trustees Of Columbia University In The City Of New York Akt and shh pathway inhibitor combination therapy for treating basal cell carcinomas
WO2017066335A1 (en) * 2015-10-12 2017-04-20 Bhagwandin Vikash J Compositions, packaged pharmaceuticals, and methods of using hedgehog pathway modulators for the sensitization of resistant tumors
JP6688884B2 (ja) * 2015-11-05 2020-04-28 ビージーアイ シェンチェン 肺腺癌を検出するためのバイオマーカー及びその使用
CN105582012A (zh) * 2016-02-29 2016-05-18 扬州艾迪生物科技有限公司 3’-羟基伊曲康唑的用途
RS66574B1 (sr) 2016-07-29 2025-03-31 Janssen Pharmaceutica Nv Niraparib za upotrebu u postupku lečenja raka prostate
WO2018031968A1 (en) 2016-08-12 2018-02-15 L.E.A.F. Holdings Group Llc Alpha and gamma-d polyglutamated antifolates and uses thereof
EP4052729A1 (en) 2016-08-12 2022-09-07 L.E.A.F Holdings Group LLC Alpha and gamma-d polyglutamated antifolates and uses thereof
WO2018191541A1 (en) * 2017-04-12 2018-10-18 Bhagwandin Vikash J Compositions, packaged pharmaceuticals, and methods of using posaconazole for the sensitization of resistant tumors
EP3624798A1 (en) * 2017-05-18 2020-03-25 Institut National de la Sante et de la Recherche Medicale (INSERM) Methods and pharmaceutical compositions for the treatment of mast cell diseases
WO2019100003A1 (en) * 2017-11-17 2019-05-23 Yoon Jaeyoung Combination therapy targeting cancer associated with the hedgehog pathway
CN111936146A (zh) 2018-02-07 2020-11-13 L.E.A.F.控股集团公司 α聚谷氨酸化四氢叶酸及其用途
WO2019157129A1 (en) 2018-02-07 2019-08-15 L.E.A.F. Holdings Group Llc Alpha polyglutamated pralatrexate and uses thereof
JP7490239B2 (ja) * 2018-02-07 2024-05-27 エル．イー．エー．エフ． ホールディングス グループ エルエルシー ガンマポリグルタミン酸化ペメトレキセドおよびその使用
US12220431B2 (en) 2018-02-07 2025-02-11 L.E.A.F. Holdings Group Llc Gamma polyglutamated antifolates and uses thereof
WO2019157138A1 (en) 2018-02-07 2019-08-15 L.E.A.F. Holdings Group Llc Alpha polyglutamated pemetrexed and uses thereof
EP3749318A4 (en) 2018-02-07 2022-07-06 L.E.A.F Holdings Group LLC GAMMA-POLYGLUTAMATED RALTITREXED AND ITS USES
WO2019157133A1 (en) 2018-02-07 2019-08-15 L.E.A.F. Holdings Group Llc Alpha polyglutamated raltitrexed and uses thereof
EP3749312A4 (en) 2018-02-07 2022-02-23 L.E.A.F Holdings Group LLC ALPHA-POLYGLUTAMATED LOMETREXOLE AND USES THEREOF
CN111867593A (zh) 2018-02-07 2020-10-30 L.E.A.F.控股集团公司 α聚谷氨酸化抗叶酸剂及其用途
CA3090384A1 (en) 2018-02-07 2019-08-15 L.E.A.F. Holdings Group Llc Alpha polyglutamated aminopterin and uses thereof
JP7462950B2 (ja) 2018-02-14 2024-04-08 エル．イー．エー．エフ． ホールディングス グループ エルエルシー ガンマポリグルタミン酸化メトトレキセートおよびその使用
US12048767B2 (en) 2018-02-14 2024-07-30 L.E.A.F. Holdings Group Llc Gamma polyglutamated pralatrexate and uses thereof
EP3755335A4 (en) 2018-02-14 2022-06-22 L.E.A.F Holdings Group LLC GAMMA POLYGLUTAMIC TETRAHYDROFOLATES AND THEIR USES
US12350271B2 (en) 2018-02-14 2025-07-08 L.E.A.F. Holdings Group Llc Gamma polyglutamated aminopterin and uses thereof
US20190365743A1 (en) * 2018-05-30 2019-12-05 Hedgepath Pharmaceuticals, Inc. Hedgehog pathway inhibition for treatment of high-risk basal cell carcinoma or high-risk basal cell carcinoma nevus syndrome
KR20220002930A (ko) * 2019-03-28 2022-01-07 캔써 리서치 테크놀로지 리미티드 비정형 단백질 키나제 c의 억제제 및 헷지호그 경로 의존성 암의 치료에서 이의 용도
CN113025614B (zh) * 2021-03-22 2022-08-19 四川大学华西医院 一种胶质瘤诊断和/或预后评估标志物及其应用
EP4323302A4 (en) 2021-04-12 2025-02-26 Structural Services, Inc. SYSTEMS AND METHODS FOR ASSISTING A CRANE OPERATOR

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001047492A1 (en) * 1999-12-23 2001-07-05 F H Faulding & Co Limited Improved pharmaceutical compositions for poorly soluble drugs

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6238876B1 (en) 1997-06-20 2001-05-29 New York University Methods and materials for the diagnosis and treatment of sporadic basal cell carcinoma
US20050130922A1 (en) 1997-06-20 2005-06-16 Altaba Ariel R.I. Method and compositions for inhibiting tumorigenesis
US6432970B2 (en) 1998-04-09 2002-08-13 Johns Hopkins University School Of Medicine Inhibitors of hedgehog signaling pathways, compositions and uses related thereto
US20070021493A1 (en) 1999-09-16 2007-01-25 Curis, Inc. Mediators of hedgehog signaling pathways, compositions and uses related thereto
DE60017157T2 (de) 1999-09-16 2005-12-22 Curis, Inc., Cambridge Vermittler von igel signalwegen, deren zusammenstellungen und verwendungen
EP1728797A3 (en) 1999-10-13 2011-03-02 Johns Hopkins University School of Medicine Regulators of the hedgehog pathway, compositions and uses related thereto
EP1227805B2 (en) 1999-10-14 2011-02-23 Curis, Inc. Mediators of hedgehog signaling pathways, compositions and uses related thereto
IL133809A0 (en) 1999-12-30 2001-04-30 Yeda Res & Dev Steroidal alkaloids and pharmaceutical compositions comprising them
AU4966401A (en) 2000-03-30 2001-10-15 Curis Inc Small organic molecule regulators of cell proliferation
CA2412215A1 (en) 2000-06-16 2001-12-27 Curis, Inc. Angiogenesis-modulating compositions and uses
NZ530580A (en) 2001-07-27 2007-02-23 Curis Inc Mediators of hedgehog signaling pathways, compositions and uses related thereto
CA2483311A1 (en) 2002-04-22 2003-10-30 Philip A. Beachy Modulators of hedgehog signaling pathways, compositions and uses related thereto
AU2003265853A1 (en) 2002-08-29 2004-03-19 Curis, Inc. Hedgehog antagonists, methods and uses related thereto
FR2850022B1 (fr) 2003-01-22 2006-09-08 Centre Nat Rech Scient Nouvelle utilisation de la mifepristone et de ses derives comme modulateurs de la voie de signalisation des proteines hedgehog et ses applications
WO2005013800A2 (en) 2003-07-15 2005-02-17 The Johns Hopkins University Elevated hedgehog pathway activity in digestive system tumors, and methods of treating digestive system tumors having elevated hedgehog pathway activity
WO2005033288A2 (en) 2003-09-29 2005-04-14 The Johns Hopkins University Hedgehog pathway antagonists
US20070231828A1 (en) * 2003-10-01 2007-10-04 Johns Hopkins University Methods of predicting behavior of cancers
US20080095761A1 (en) 2003-10-01 2008-04-24 The Johns Hopkins University Hedgehog Signaling in Prostate Regeneration Neoplasia and Metastasis
WO2005042700A2 (en) 2003-10-20 2005-05-12 The Johns Hopkins University Use of hedgehog pathway inhibitors in small-cell lung cancer
JP4836798B2 (ja) * 2003-10-21 2011-12-14 アイジーエフ オンコロジー エルエルシー 癌を治療するための化合物および方法
CA2565237C (en) 2004-04-30 2012-12-11 Genentech, Inc. Quinoxaline inhibitors of hedgehog signalling
EP1765336A4 (en) 2004-06-25 2010-03-10 Univ Johns Hopkins ANGIOGENESIS INHIBITORS
EP2316832B1 (en) 2004-08-27 2017-03-08 Infinity Pharmaceuticals, Inc. Cyclopamine analogues and methods of use thereof
PT1789390E (pt) 2004-09-02 2012-02-08 Genentech Inc Inibidores de piridilo da sinalização de hedgehog
RU2007119637A (ru) 2004-10-28 2008-12-10 Айрм Ллк (Bm) Соединения и композиции в качестве модуляторов hedgehog-пути
US8653083B2 (en) 2005-08-22 2014-02-18 The Johns Hopkins University Hedgehog pathway antagonists to treat disease
WO2007054623A2 (en) 2005-11-11 2007-05-18 Licentia Oy Mammalian hedgehog signaling inhiabitors
ES2604539T3 (es) 2005-11-14 2017-03-07 Genentech, Inc. Inhibidores de tipo bisamida de la señalización hedgehog
WO2008121102A2 (en) 2006-02-21 2008-10-09 The Regents Of The University Of Michigan Hedgehog signaling pathway antagonist cancer treatment
JP2009536156A (ja) 2006-04-14 2009-10-08 ノバルティス アクチエンゲゼルシャフト ヘッジホッグ経路関連障害の処置におけるビアリールカルボキサミドの使用
UA93548C2 (uk) 2006-05-05 2011-02-25 Айерем Елелсі Сполуки та композиції як модулятори хеджхогівського сигнального шляху
SG175691A1 (en) 2006-10-31 2011-11-28 Us Gov Health & Human Serv Smoothened polypeptides and methods of use
TWI433674B (zh) 2006-12-28 2014-04-11 Infinity Discovery Inc 環杷明（ｃｙｃｌｏｐａｍｉｎｅ）類似物類
US7648994B2 (en) 2007-03-07 2010-01-19 Infinity Discovery, Inc. Heterocyclic cyclopamine analogs and methods of use thereof
EP2134719B1 (en) 2007-03-07 2013-07-17 Infinity Discovery, Inc. Cyclopamine lactam analogs and methods of use thereof
BRPI0808772A2 (pt) 2007-03-14 2014-08-12 Exelixis Inc Inibidores da via de hedgehog
SG182205A1 (en) 2007-03-15 2012-07-30 Novartis Ag Organic compounds and their uses
US9095589B2 (en) 2007-04-05 2015-08-04 Johns Hopkins University Chirally pure isomers of itraconazole for use as angiogenesis inhibitors
CN101711156A (zh) 2007-04-05 2010-05-19 约翰·霍普金斯大学 作为血管新生抑制剂的伊曲康唑的手性纯的异构物及羊毛甾醇14a-去甲基酶的抑制剂
WO2008131354A2 (en) 2007-04-20 2008-10-30 The Curators Of The University Of Missouri Phytoestrogens as regulators of hedgehog signaling and methods of their use in cancer treatment
EP2227456A2 (en) 2007-12-13 2010-09-15 Siena Biotech S.p.A. Hedgehog pathway antagonists and therapeutic applications thereof
CN102083801A (zh) 2008-03-28 2011-06-01 康瑟特制药公司 喹唑啉衍生物和治疗方法
WO2009140675A2 (en) 2008-05-16 2009-11-19 Pharma Mar, S.A. Combination therapy with an antitumor alkaloid
WO2010030948A2 (en) 2008-09-12 2010-03-18 The Board Of Trustees Of The Leland Stanford Junior University Hedgehog signaling and cancer stem cells in hematopoietic cell malignancies
WO2011088404A1 (en) 2010-01-15 2011-07-21 Infinity Pharmaceuticals , Inc Treatment of fibrotic conditions using hedgehog inhibitors
US9346791B2 (en) 2011-09-07 2016-05-24 The Johns Hopkins University Itraconazole analogs and use thereof
AU2012304407A1 (en) 2011-09-09 2014-04-24 Children's Hospital & Research Center Oakland Topical itraconazole formulations and uses thereof
CN102319260A (zh) * 2011-09-21 2012-01-18 广州维美投资有限公司 顺铂联合伊曲康唑异构体在制备治疗肺癌药物中的应用
GB201201298D0 (en) 2012-01-26 2012-03-07 Universitat Leipzig Therapeutic use of activators of zinc finger protein gli3
JP2015531749A (ja) 2012-06-21 2015-11-05 メイン ファーマ インターナショナル プロプライエタリー リミテッドＭａｙｎｅ Ｐｈａｒｍａ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｐｔｙ．Ｌｔｄ． イトラコナゾール組成物及び投与剤形、並びにその使用方法
CA2913634C (en) 2013-06-07 2022-08-09 The California Institute For Biomedical Research Small molecule inhibitors of fibrosis
WO2015073691A1 (en) 2013-11-14 2015-05-21 The Board Of Trustees Of The Leland Stanford Junior University Methods for treating cancer by activation of bmp signaling
WO2015116947A1 (en) 2014-02-01 2015-08-06 University Of Connecticut Itraconazole analogues and methods of use thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001047492A1 (en) * 1999-12-23 2001-07-05 F H Faulding & Co Limited Improved pharmaceutical compositions for poorly soluble drugs

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ANTONARAKIS等: "Repurposing itraconazole as a treatment for advanced prostate cancer a noncomparative randomized phase II trial in men with metastatic castration-resistant prostate cancer", 《THE ONCOLOGIST》 *

Also Published As

Publication number Publication date
EP2986296A4 (en) 2016-11-23
US20180243295A1 (en) 2018-08-30
WO2014172456A1 (en) 2014-10-23
MX2015014660A (es) 2016-07-05
HUE071728T2 (hu) 2025-09-28
DK2986296T3 (da) 2025-06-23
US20180243296A1 (en) 2018-08-30
AU2019203995B2 (en) 2020-06-25
EP2986296A1 (en) 2016-02-24
ES3033763T3 (en) 2025-08-07
JP2016518371A (ja) 2016-06-23
US20190255045A1 (en) 2019-08-22
MX383296B (es) 2025-03-13
CA2909290A1 (en) 2014-10-23
AU2019203995C1 (en) 2020-10-15
US9968600B2 (en) 2018-05-15
US20190255044A1 (en) 2019-08-22
US20170136011A1 (en) 2017-05-18
PL2986296T3 (pl) 2025-07-21
US10328072B2 (en) 2019-06-25
US9962381B2 (en) 2018-05-08
US20160074393A1 (en) 2016-03-17
BR112015025944A2 (pt) 2017-07-25
CA2909290C (en) 2022-11-29
KR20160053843A (ko) 2016-05-13
BR112015025944A8 (pt) 2020-01-14
JP2019151652A (ja) 2019-09-12
US9192609B2 (en) 2015-11-24
US20170136012A1 (en) 2017-05-18
AU2014253998A1 (en) 2015-11-05
CN105722512A (zh) 2016-06-29
US20140315920A1 (en) 2014-10-23
US10363252B2 (en) 2019-07-30
US20200375985A1 (en) 2020-12-03
AU2019203995A1 (en) 2019-06-27
EP2986296B1 (en) 2025-06-04
US20160074392A1 (en) 2016-03-17

Similar Documents

Publication Publication Date Title
CN112043829A (zh) 使用hedgehog途径抑制剂对增殖性病症的治疗和预后监测
EP2908132B1 (en) Prediction of drug sensitivity of lung tumors based on molecular and genetic signatures
JP2019531699A (ja) Ｎｒｆ２及びその遺伝子の下流標的遺伝子の発現状態及び変異状態によるがんの診断及び治療方法
Palisoul et al. Identification of molecular targets in vulvar cancers
CN104302286A (zh) 用于治疗乳腺癌的curaxin和用于鉴别可能响应的患者的方法
HK1226320A1 (en) Treatment and prognostic monitoring of proliferation disorders using hedgehog pathway inhibitors
EP3814349A1 (en) Hedgehog pathway inhibition for treatment of high-risk basal cell carcinoma or high-risk basal cell carcinoma nevus syndrome
JP6478417B2 (ja) 大腸癌患者の生存を予測及び改善するための方法
WO2024201340A1 (en) Kat6a as a predictive biomarker for treatment of breast cancer with a cdk4 inhibitor and an antiestrogen and methods of treatment thereof
KR20250164842A (ko) Kat6a 억제제에 의한 치료를 위한 예측 바이오마커로서의 kat6a 및 이의 치료 방법

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20201208